ARCT
Arcturus Therapeutics Holdings Inc
NASDAQ: ARCT · HEALTHCARE · BIOTECHNOLOGY
$8.40
-5.30% today
Updated 2026-04-29
Market cap
$238.75M
P/E ratio
—
P/S ratio
2.91x
EPS (TTM)
$-2.40
Dividend yield
—
52W range
$6 – $24
Volume
0.5M
WallStSmart proprietary scores
29
out of 100
Grade: F
Strong Sell
Investment rating
2.7
Growth
F6.0
Quality
B2.0
Profitability
F6.7
Valuation
B1/9
Piotroski F-Score
Weak
-0.1
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →201 stocks currently score above 75
Price targets
Analyst target
$23.30
+177.38%
12-Month target
—
—
Intrinsic (DCF)
$55.99
Margin of safety
+86.78%
2 Strong Buy8 Buy3 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ 86.78% below intrinsic value
+ Debt/equity 0.10x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -0.11 — distress zone
- Thin margins at -80.20%
- Negative free cash flow $-16.36M
- Revenue declining -68.40% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $205.75M | $157.75M | $138.39M | $67.22M | $82.03M |
| Net income | $9.35M | $-29.73M | $-80.94M | $-65.78M | $-29.08M |
| EPS | — | — | — | — | $-2.40 |
| Free cash flow | $24.27M | $-21.00M | $-60.40M | $-74.50M | $-16.36M |
| Profit margin | 4.54% | -18.84% | -58.49% | -97.86% | -80.20% |
Peer comparison
Smart narrative
Arcturus Therapeutics Holdings Inc trades at $8.40. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -0.11, it sits in the distress. TTM revenue stands at $82.03M. with profit margins at -80.20%. Our DCF model estimates intrinsic value at $55.99.
Frequently asked questions
What is Arcturus Therapeutics Holdings Inc's stock price?
Arcturus Therapeutics Holdings Inc (ARCT) trades at $8.40.
Is Arcturus Therapeutics Holdings Inc overvalued?
Smart Value Score 29/100 (Grade F, Strong Sell). DCF value $55.99.
What is the price target of Arcturus Therapeutics Holdings Inc (ARCT)?
The analyst target price is $23.30, representing +177.4% upside from the current price of $8.40.
What is the intrinsic value of Arcturus Therapeutics Holdings Inc (ARCT)?
Based on our DCF model, intrinsic value is $55.99, a +86.8% margin of safety versus $8.40.
What is Arcturus Therapeutics Holdings Inc's revenue?
TTM revenue is $82.03M.
Piotroski F-Score?
1/9 — weak financial health.
Altman Z-Score?
-0.11 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.91x
ROE-28.90%
Beta2.44
50D MA$7.80
200D MA$11.05
Shares out0.03B
Float0.03B
Short ratio—
Avg volume0.5M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—